ONCAlert | 2018 ASCO Annual Meeting

Efficacy and Biomarker Results for Pembrolizumab in Soft Tissue and Bone Sarcomas

Lisa H. Butterfield, PhD
Published Online: 10:15 PM, Fri June 2, 2017

Lisa H. Butterfield, PhD, professor of Medicine, Surgery, and Immunology, University of Pittsburgh, discusses efficacy and biomarker results of the phase II SARC028 study, which explored pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas, during the 2017 ASCO Annual Meeting.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.